# Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer

Source: https://onco.cc/trials/nct01054079/  
OnCo record `nct01054079` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Cinacalcet in Prostate cancer, run by Wake Forest University Health Sciences, completed.

## Summary

Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer is a phase 2 interventional study registered as NCT01054079 by Wake Forest University Health Sciences, with 20 participants recorded, started 2011-09 and reaching its primary completion in 2014-08. Interventions recorded: laboratory biomarker analysis, quality-of-life assessment, questionnaire administration, cinacalcet hydrochloride. Conditions recorded: Adenocarcinoma of the Prostate, Recurrent Prostate Cancer.

Linked to the drug Cinacalcet because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01054079
- Phase: 2
- Setting: A Phase II Trial to Assess the Effect of Cinacalcet Hydrochloride on PSA Levels in Patients With Biochemically Recurrent Prostate Cancer After Failed Definitive Local Therapy
- Sponsor: Wake Forest University Health Sciences
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT01054079: https://clinicaltrials.gov/study/NCT01054079

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Cinacalcet](https://onco.cc/drugs/cinacalcet/)

---
JSON: https://onco.cc/api/v1/entities/nct01054079.json